A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

← catalyst calendar

NCT07159841 · readout ≤ 1,320 d

Sponsored by Crinetics Pharmaceuticals Inc. (industry) · CRNX — their whole pipeline →.

Phase

Phase 2/3

Status

Recruiting

Study type

Interventional

Design

Randomized · Triple · Treatment

Enrollment

153estimated

Sites

Countries

Argentina, Australia, Belgium +9

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-01-22

actual

When the study began enrolling

Primary completion

Mar 2030

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Mar 2030

estimated

The whole study's end, after follow-up

First posted

2025-09-08

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-12

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Congenital Adrenal Hyperplasia
Classic Congenital Adrenal Hyperplasia

Interventions

Drug: Atumelnant — also filed as CRN04894
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Change from baseline in morning serum androstenedione (A4) (Part A)

measured Week 8

Percent change from baseline in glucocorticoid (GC) daily dose while serum early morning A4 ≤Upper Limit of Normal (ULN) (Part B)

measured Week 28

Change from baseline in serum early morning A4 over time (Part C)

measured Up to Week 260

Permalink · CRNX's whole pipeline · Catalyst calendar · Every registered study · What changed